Publications 2025

Anthi AK, Kolderup A, Vaage EB, Bern M, Benjakul S, Tjärnhage E, Ruso-Julve F, Jensen KR, Lode HE, Vaysburd M, Nilsen J, Herigstad ML, Sakya SA, Tietze L, Pilati D, Nyquist-Andersen M, Dürkoop M, Gjølberg TT, Peng L, Foss S, Moe MC, Low BE, Wiles MV, Nemazee D, Jahnsen FL et al. (2025)
An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models
Nat Commun, 16 (1), 3999
DOI 10.1038/s41467-025-59353-6, PubMed 40312392

Mester S, Chan C, Lustig M, Foss S, Jansen JHM, Leangen Herigstad M, Evers M, Nilsen J, Reiding KR, A Damen JM, Burger R, Grevys A, Dalhus B, Valerius T, Sandlie I, Leusen JHW, Andersen JT (2025)
Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life
PNAS Nexus, 4 (2), pgaf042
DOI 10.1093/pnasnexus/pgaf042, PubMed 40041621

Nilsen J, Aaen KH, Benjakul S, Ruso-Julve F, Greiner TU, Bejan D, Stensland M, Singh S, Schlothauer T, Sandlie I, Andersen JT (2025)
Enhanced plasma half-life and efficacy of engineered human albumin-fused GLP-1 despite enzymatic cleavage of its C-terminal end
Commun Biol, 8 (1), 810
DOI 10.1038/s42003-025-08249-8, PubMed 40419755

Trabjerg E, Nilsen J, Tollefsrud Gjølberg T, Andersen JT, Leitner A, Rand KD (2025)
Identification of a direct interaction between the Fab domains of IgG antibodies and human FcRn upon IgG-FcRn complex formation
Commun Biol, 8 (1), 922
DOI 10.1038/s42003-025-08252-z, PubMed 40506471

Publications 2022

Grevys A, Frick R, Mester S, Flem-Karlsen K, Nilsen J, Foss S, Sand KMK, Emrich T, Fischer JAA, Greiff V, Sandlie I, Schlothauer T, Andersen JT (2022)
Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life
iScience, 25 (2), 103746
DOI 10.1016/j.isci.2022.103746, PubMed 35118359

Publications 2021

Azevedo C, Pinto S, Benjakul S, Nilsen J, Santos HA, Traverso G, Andersen JT, Sarmento B (2021)
Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery
Adv Drug Deliv Rev, 175, 113778
DOI 10.1016/j.addr.2021.04.016, PubMed 33887405

Lombardi S, Aaen KH, Nilsen J, Ferrarese M, Gjølberg TT, Bernardi F, Pinotti M, Andersen JT, Branchini A (2021)
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity
Br J Haematol, 194 (2), 453-462
DOI 10.1111/bjh.17559, PubMed 34109608

Merten H, Brandl F, Zimmermann M, Schaefer JV, Irpinio L, Sand KMK, Nilsen J, Andersen JT, Zangemeister-Wittke U, Plückthun A (2021)
Half-life extension of efficiently produced DARPin serum albumin fusions as a function of FcRn affinity and recycling
Eur J Pharm Biopharm, 167, 104-113
DOI 10.1016/j.ejpb.2021.07.011, PubMed 34303832

Mester S, Evers M, Meyer S, Nilsen J, Greiff V, Sandlie I, Leusen J, Andersen JT (2021)
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
MAbs, 13 (1), 1893888
DOI 10.1080/19420862.2021.1893888, PubMed 33691596

Aaen KH, Anthi AK, Sandlie I, Nilsen J, Mester S, Andersen JT (2021)
The neonatal Fc receptor in mucosal immune regulation
Scand J Immunol, 93 (2), e13017
DOI 10.1111/sji.13017, PubMed 33351196

Publications 2020

Azevedo C, Nilsen J, Grevys A, Nunes R, Andersen JT, Sarmento B (2020)
Engineered albumin-functionalized nanoparticles for improved FcRn binding enhance oral delivery of insulin
J Control Release, 327, 161-173
DOI 10.1016/j.jconrel.2020.08.005, PubMed 32771477

Bern M, Nilsen J, Ferrarese M, Sand KMK, Gjølberg TT, Lode HE, Davidson RJ, Camire RM, Bækkevold ES, Foss S, Grevys A, Dalhus B, Wilson J, Høydahl LS, Christianson GJ, Roopenian DC, Schlothauer T, Michaelsen TE, Moe MC, Lombardi S, Pinotti M, Sandlie I, Branchini A, Andersen JT (2020)
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics
Sci Transl Med, 12 (565)
DOI 10.1126/scitranslmed.abb0580, PubMed 33055243

Nilsen J, Trabjerg E, Grevys A, Azevedo C, Brennan SO, Stensland M, Wilson J, Sand KMK, Bern M, Dalhus B, Roopenian DC, Sandlie I, Rand KD, Andersen JT (2020)
An intact C-terminal end of albumin is required for its long half-life in humans
Commun Biol, 3 (1), 181
DOI 10.1038/s42003-020-0903-7, PubMed 32313072

Publications 2018

Grevys A, Nilsen J, Sand KMK, Daba MB, Øynebråten I, Bern M, McAdam MB, Foss S, Schlothauer T, Michaelsen TE, Christianson GJ, Roopenian DC, Blumberg RS, Sandlie I, Andersen JT (2018)
A human endothelial cell-based recycling assay for screening of FcRn targeted molecules
Nat Commun, 9 (1), 621
DOI 10.1038/s41467-018-03061-x, PubMed 29434196

Nilsen J, Bern M, Sand KMK, Grevys A, Dalhus B, Sandlie I, Andersen JT (2018)
Human and mouse albumin bind their respective neonatal Fc receptors differently
Sci Rep, 8 (1), 14648
DOI 10.1038/s41598-018-32817-0, PubMed 30279529

Nilsen J, Sandlie I, Roopenian DC, Andersen JT (2018)
Animal models for evaluation of albumin-based therapeutics
Curr. Opin. Chem. Eng., 19, 68-76
DOI 10.1016/j.coche.2017.11.007

Publications 2015

Bern M, Sand KM, Nilsen J, Sandlie I, Andersen JT (2015)
The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery
J Control Release, 211, 144-62
DOI 10.1016/j.jconrel.2015.06.006, PubMed 26055641

Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT (2015)
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
Front Immunol, 5, 682
DOI 10.3389/fimmu.2014.00682, PubMed 25674083

Publications 2014

Sand KM, Bern M, Nilsen J, Dalhus B, Gunnarsen KS, Cameron J, Grevys A, Bunting K, Sandlie I, Andersen JT (2014)
Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn)
J Biol Chem, 289 (50), 34583-94
DOI 10.1074/jbc.M114.587675, PubMed 25344603